Physician profile
Sue C Eng
NPI 1184603425
$3,810.58
in general payments reported to CMS, 2019-2025
24 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $199 · 2021: $529 · 2022: $586 · 2023: $763 · 2024: $939 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.99 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $714.47 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $485.74 | 2022-2024 | Zeposia |
| Abbvie INC. | $399.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.56 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.75 | 2021-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $241.13 | 2022-2025 | |
| Boston Scientific Corporation | $171.09 | 2019-2023 | Compliance Endokit |
| Genzyme Corporation | $168.47 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $164.92 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $102.62 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $101.14 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $100.66 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $100.13 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $98.91 | 2021 | |
| Braintree Laboratories, INC. | $93.10 | 2021-2024 | Suflave |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $81.81 | 2021-2023 | |
| Madrigal Pharmaceuticals | $46.89 | 2024 | Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $32.23 | 2021 | |
| Merck Sharp & Dohme LLC | $26.35 | 2023 | Dificid |
| Organon LLC | $25.89 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $24.35 | 2025 | Iqirvo |
| Novo Nordisk INC | $22.95 | 2025 | Wegovy |
| Ardelyx, INC. | $14.28 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.